Pharmacy Website
Clinic Website

Intelligence » Diabetes

Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial

Thursday, December 20, 2018 -- OBJECTIVE To determine the risk factors for severe hypoglycemia and the association between severe hypoglycemia and serious cardiovascular adverse events and cardiovascular and all-cause mortality in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS This post hoc analysis of data from the VADT included 1,791 military veterans (age 60.5 ± 9.0 years) with suboptimally controlled type 2 diabetes (HbA1c 9.4 ± 2.0%) of 11.5 ± 7.5 years disease duration with or without known cardiovascular disease and additional cardiovascular risk factors. Participants were randomized to intensive (HbA1c <7.0%) versus standard (HbA1c <8.5%) glucose control. RESULTS The rate of severe hypoglycemia in the intensive treatment group was 10.3 per 100 patient-years compared with 3.7 per 100 patient-years in the

Subscribe to get latest posts via email or subscribe to a RSS feed.

Related News

Gene Transfer Improved Cardiac Function in Diabetic Mouse Model

Thursday, March 28, 2019 -- The concept of a single administration of an agent that reduces blood sugar while increasing heart function, would be attractive to patients with diabete Continue reading →

Diabetes group nods to Vascepa, sending Amarin stock higher

Thursday, March 28, 2019 -- The ADA updated its medical care standards to include Vascepa, as Amarin works to apply for an expanded heart label for the drug.

NICE backs funding for MSD's diabetes drug Steglatro

Thursday, March 28, 2019 -- NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same class. The cost-effectiveness body recommended Steglatro (...

First-trimester proteomic profiling identifies novel predictors of gestational diabetes mellitus

Wednesday, March 27, 2019 -- by Tina Ravnsborg, Sarah Svaneklink, Lise Lotte T. Andersen, Martin R. Larsen, Dorte M. Jensen, Martin Overgaard Background Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with adverse outcomes including preeclampsia, caesarean section, macrosomia, neonatal morbidity and future development of type 2 diabetes in both mother and child. Current selective screening strategies rely on clinical risk factors such as age, family history of diabetes, macrosomia or GDM in a previous pregnancy, and they possess a relatively low specificity. Here we hypothesize that novel first trimester protein predictors of GDM can contribute to the current selective screening strategies for early and accurate prediction of GDM, thus allowing for timely interventions. Methods A proteomics discovery approach was applied to

Women Face Greater Barriers in Type 2 Diabetes Care

Wednesday, March 27, 2019 -- Does diabetes treatment access differ significantly between men and women? A recent review of peer-reviewed literature concerning the difference in type 2 diabetes care between men and women suggests that women face greater challenges. Study Design The review authors conducted a search of peer-reviewed literature published between 2005 and 2017 that investigated the differences in […]

Diabetes in pregnancy tied to future heart disease risk

Wednesday, March 27, 2019 -- (Reuters Health) - Women with pregnancy-related diabetes are at higher risk for developing cardiovascular disease in the decade after childbirth, a research review suggests.

Sign Up